Outcomes4Me’s Post

Join CURE and West Cancer Center & Research Institute on October 4th at 4:40 PM in Germantown, TN, for Educated Patient Updates in Metastatic Breast Cancer. Hear from experts like Dr. Gregory Vidal and connect with fellow patients and caregivers. Knowledge you'll walk away with includes: • Understanding metastatic breast cancer and its subtypes • Initial hormone therapy for treatment of ER+/HER2- metastatic breast cancer • Biomarkers: What they are and why we test for them • Next hormone therapy for ER+/HER2- metastatic breast cancer that progresses or stops responding • A hypothetical example of a patient’s treatment strategy Reserve your seat today: https://bit.ly/3sZQXGC

NEW: Highlights from #SABCS2023: #novelagents and insights on #HER2 dynamics in #breastcancer 🇺🇸 🎥 Kevin Kalinsky, MD, MS, from the Winship Cancer Institute of Emory University, discusses exciting posters presented during the spotlight session at the San Antonio Breast Cancer Symposium (SABCS) 2023 💡The main focus is on new agents, including two #bispecificantibodies and a TROP-2 #antibodydrugconjugate (ADC) 💡A real-world analysis, RELIEVE, underscores the importance of #HER2 dynamics, revealing potential differences in outcomes for patients with #HER2-low #primarytumors and #metastatic tumors 💡The discussion emphasizes considerations about #toxicities, responses, and the optimal measurement of targets, questioning whether #targetedtherapies induce bystander effects that render assays less critical Take a look 👉 https://lnkd.in/ethirU9d Check out our #SABCS page for all the latest coverage 👉 https://lnkd.in/eYrYkh5C #SABCS23 #BreastCancer #BCsm #breastcancerawareness  American Association for Cancer Research

Educated Patient® Metastatic Breast Cancer Updates   Sara M. Tolaney, MD, MPH, an expert breast medical oncologist, provides insights on navigating a diagnosis of HER2+ metastatic breast cancer, explains the current treatment options, and shares tips for managing potential side effects and communicating with an oncology care team. EP. 1: The Role of the HER2 Receptor in Breast Cancer Sara M. Tolaney, MD, MPH, introduces the role of HER2 as a breast cancer cell growth receptor and explains HER2-positive versus HER2-negative. EP. 2: Necessary Tests After a Diagnosis of Breast Cancer Sara M. Tolaney, MD, MPH, states that all breast cancers should be tested for estrogen, progesterone, and HER2 receptors; HER2 testing involves an immunohistochemistry stain to quantify protein levels, with 3+ indicating HER2+ disease, 0 indicating HER2- disease, and 1-2+ levels needing additional FISH testing to clarify HER2 status.

More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision medicine trials—ComboMATCH, MyeloMATCH, and iMATCH—are getting underway to build on the knowledge generated by NCI-MATCH and other NCI precision oncology initiatives. So, what comes next after NCI-MATCH? James H. Doroshow, M.D., director of NCI Division of Cancer Treatment and Diagnosis, reflects on the accomplishments of NCI-MATCH and offers an overview of these three successor trials. #CancerResearch #PrecisionOncology

🎗️In honor of #BreastCancerAwarenessMonth, we're excited to share the first episode of an insightful animated video series following a patient's #BreastCancer journey from diagnosis to selecting the best treatment options. In this first episode, oncology expert Prof. François-Clément Bidard, sheds light on metastatic breast cancer treatment, guiding you through the key steps to enhance treatment decision-making for #ER+/HER2- metastatic breast cancer patients. Learn more about: 🔍 Patient-specific molecular characterization 🧪 ESR1 mutation testing 📋 ER+ metastatic breast cancer treatment guidelines Watch the video and download the presentation slides for 🆓! 👉🏼https://ow.ly/RJUA50PZkp5 #MedEd

KN495 updated clinical manuscript entitled “Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results” has been epublished by Nature Medicine on July 10 - Jianda Yuan #cancer #biomarker #epublished #immunotherapy #pembrolizumab #oncology #oncodaily

Exai Bio to Present New Breast Cancer Data at the American Association for Cancer Research (AACR) 2024 Annual Meeting PALO ALTO, Calif.--(BUSINESS WIRE)--Exai Bio today announced new breast cancer data at the American Association for Cancer Research (AACR) 2024 annual meeting. In a new study, Exai’s novel RNA- and AI-based liquid biopsy platform demonstrated stage I breast cancer detection sensitivity of 90% and ductal carcinoma in situ (DCIS) sensitivity of 88%, both at 90% specificity. In addition, the study showed the platform’s unique capability to distinguish low grade, less aggressive DCIS. via Business Wire Health: Medical Devices News April 08, 2024 at 11:30PM